Creative Planning
CYTK icon

Creative Planning’s Cytokinetics CYTK Stock Holding History

Creative Planning’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1M Buy
141,939
+34,179
+32% +$2.45M 0.01% 749
2026
Q1 		$7.1M Buy
107,760
+10,821
+11% +$688K ﹤0.01% 934
2025
Q4 		$6.16M Buy
96,939
+9,629
+11% +$599K ﹤0.01% 865
2025
Q3 		$4.8M Buy
87,310
+39,248
+82% +$1.62M ﹤0.01% 911
2025
Q2 		$1.59M Buy
48,062
+14,485
+43% +$504K ﹤0.01% 1494
2025
Q1 		$1.35M Buy
33,577
+12,273
+58% +$564K ﹤0.01% 1480
2024
Q4 		$1M Sell
21,304
-2,362
-10% -$123K ﹤0.01% 1642
2024
Q3 		$1.25M Buy
23,666
+7,939
+50% +$442K ﹤0.01% 1348
2024
Q2 		$852K Buy
15,727
+5,649
+56% +$341K ﹤0.01% 1533
2024
Q1 		$707K Buy
10,078
+3,607
+56% +$279K ﹤0.01% 1589
2023
Q4 		$540K Buy
+6,471
New +$234K ﹤0.01% 1660
2017
Q3 		– Sell
-83
Closed -$1K – 2293
2017
Q2 		$1K Sell
83
-42
-34% -$584 ﹤0.01% 4416
2017
Q1 		$2K Buy
125
+42
+51% +$491 ﹤0.01% 4268
2016
Q4 		$1K Hold
83
– – ﹤0.01% 4408
2016
Q3 		$1K Hold
83
– – ﹤0.01% 4363
2016
Q2 		$1K Hold
83
– – ﹤0.01% 4149
2016
Q1 		$1K Hold
83
– – ﹤0.01% 4096
2015
Q4 		$1K Hold
83
– – ﹤0.01% 4191
2015
Q3 		$1K Sell
83
-93,026
-100% -$635K ﹤0.01% 4076
2015
Q2 		$626K Buy
93,109
+93,026
+112,080% +$610K 0.01% 605
2015
Q1 		$1K Sell
83
-250
-75% -$1.87K ﹤0.01% 4006
2014
Q4 		$3K Buy
333
+250
+301% +$1.07K ﹤0.01% 3689
2014
Q3 		$0 Hold
83
– – ﹤0.01% 4018
2014
Q2 		$0 Hold
83
– – ﹤0.01% 3803
2014
Q1 		$1K Hold
83
– – ﹤0.01% 3484
2013
Q4 		$1K Hold
83
– – ﹤0.01% 3201
2013
Q3 		$1K Buy
+83
New +$890 ﹤0.01% 3081

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Creative Planning's CYTK Position: Q2 2026 in Review

Creative Planning increased its Cytokinetics (CYTK) stake by 32% in Q2 2026, buying an estimated $2.45M and bringing the position to 141,939 shares worth $12.1M. The position accounts for 0.01% of the portfolio, ranked #749.

Creative Planning first reported a position in CYTK in Q3 2013 and has held it in 27 quarters since. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Creative Planning held 141,939 shares of Cytokinetics worth $12.1M as of Q2 2026.
  • Creative Planning bought 34,179 Cytokinetics shares in Q2 2026, an estimated $2.45M.
  • Cytokinetics made up 0.01% of Creative Planning's portfolio in Q2 2026, its #749 holding.
  • Creative Planning first reported a position in Cytokinetics in Q3 2013 and has held it in 27 quarters since.
  • 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.